1. Home
  2. WIMI vs SKYE Comparison

WIMI vs SKYE Comparison

Compare WIMI & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WIMI
  • SKYE
  • Stock Information
  • Founded
  • WIMI 2015
  • SKYE 2012
  • Country
  • WIMI China
  • SKYE United States
  • Employees
  • WIMI N/A
  • SKYE N/A
  • Industry
  • WIMI Computer Software: Prepackaged Software
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • WIMI Technology
  • SKYE Health Care
  • Exchange
  • WIMI Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • WIMI 92.2M
  • SKYE 80.7M
  • IPO Year
  • WIMI 2020
  • SKYE N/A
  • Fundamental
  • Price
  • WIMI $0.89
  • SKYE $2.85
  • Analyst Decision
  • WIMI
  • SKYE Buy
  • Analyst Count
  • WIMI 0
  • SKYE 6
  • Target Price
  • WIMI N/A
  • SKYE $18.67
  • AVG Volume (30 Days)
  • WIMI 4.6M
  • SKYE 202.8K
  • Earning Date
  • WIMI 01-01-0001
  • SKYE 02-18-2025
  • Dividend Yield
  • WIMI N/A
  • SKYE N/A
  • EPS Growth
  • WIMI N/A
  • SKYE N/A
  • EPS
  • WIMI N/A
  • SKYE N/A
  • Revenue
  • WIMI $84,137,968.00
  • SKYE N/A
  • Revenue This Year
  • WIMI N/A
  • SKYE N/A
  • Revenue Next Year
  • WIMI N/A
  • SKYE N/A
  • P/E Ratio
  • WIMI N/A
  • SKYE N/A
  • Revenue Growth
  • WIMI 19.25
  • SKYE N/A
  • 52 Week Low
  • WIMI $0.63
  • SKYE $2.31
  • 52 Week High
  • WIMI $2.92
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • WIMI 43.32
  • SKYE 46.60
  • Support Level
  • WIMI $0.86
  • SKYE $2.60
  • Resistance Level
  • WIMI $0.92
  • SKYE $3.54
  • Average True Range (ATR)
  • WIMI 0.10
  • SKYE 0.50
  • MACD
  • WIMI -0.01
  • SKYE 0.02
  • Stochastic Oscillator
  • WIMI 11.35
  • SKYE 18.60

About WIMI WiMi Hologram Cloud Inc.

WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings primarily consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: